Shares of Entellus Medical, Inc. (NASDAQ:ENTL) have been assigned a consensus rating of “Hold” from the ten ratings firms that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $21.33.

A number of equities research analysts recently weighed in on the stock. BidaskClub lowered shares of Entellus Medical from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. Canaccord Genuity restated a “hold” rating and issued a $17.00 target price on shares of Entellus Medical in a report on Tuesday, October 17th. Piper Jaffray Companies restated a “buy” rating on shares of Entellus Medical in a report on Wednesday, July 12th. Finally, Zacks Investment Research upgraded shares of Entellus Medical from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st.

Shares of Entellus Medical (ENTL) opened at 17.48 on Friday. The firm’s market capitalization is $443.49 million. The stock’s 50 day moving average price is $18.29 and its 200-day moving average price is $18.29. Entellus Medical has a 12 month low of $12.31 and a 12 month high of $20.46.

Entellus Medical (NASDAQ:ENTL) last announced its quarterly earnings data on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.03). Entellus Medical had a negative net margin of 41.11% and a negative return on equity of 60.34%. The company had revenue of $22.10 million for the quarter, compared to analyst estimates of $21.87 million. During the same quarter in the prior year, the company posted ($0.27) EPS. Entellus Medical’s revenue for the quarter was up 18.0% on a year-over-year basis. On average, equities research analysts predict that Entellus Medical will post ($1.61) EPS for the current fiscal year.

In related news, Director Brian E. Farley sold 40,000 shares of the company’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $19.78, for a total value of $791,200.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP Kevin L. Mensink sold 2,500 shares of the company’s stock in a transaction dated Friday, October 20th. The stock was sold at an average price of $19.00, for a total transaction of $47,500.00. The disclosure for this sale can be found here. Insiders sold a total of 92,150 shares of company stock worth $1,740,652 in the last 90 days. 7.70% of the stock is currently owned by company insiders.

A number of hedge funds have recently modified their holdings of ENTL. Bank of America Corp DE grew its position in Entellus Medical by 53.8% in the 1st quarter. Bank of America Corp DE now owns 7,418 shares of the medical technology company’s stock worth $102,000 after purchasing an additional 2,594 shares in the last quarter. Nationwide Fund Advisors grew its position in Entellus Medical by 61.7% in the 2nd quarter. Nationwide Fund Advisors now owns 6,903 shares of the medical technology company’s stock worth $114,000 after purchasing an additional 2,635 shares in the last quarter. First Mercantile Trust Co. grew its position in Entellus Medical by 45.3% in the 2nd quarter. First Mercantile Trust Co. now owns 8,206 shares of the medical technology company’s stock worth $136,000 after purchasing an additional 2,557 shares in the last quarter. Parametric Portfolio Associates LLC grew its position in Entellus Medical by 5.6% in the 1st quarter. Parametric Portfolio Associates LLC now owns 10,888 shares of the medical technology company’s stock worth $150,000 after purchasing an additional 573 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in Entellus Medical by 61.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,881 shares of the medical technology company’s stock worth $196,000 after purchasing an additional 4,533 shares in the last quarter. 70.27% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Entellus Medical, Inc. (ENTL) Receives Consensus Rating of “Hold” from Brokerages” was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/29/entellus-medical-inc-entl-receives-consensus-rating-of-hold-from-brokerages.html.

Entellus Medical Company Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Analyst Recommendations for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.